Eupnoos utilizes acoustic biomarkers and a smartphone app to analyze breath sounds for the rapid diagnosis of respiratory conditions such as asthma and COPD, achieving diagnostic accuracies of up to 94%. This technology eliminates the need for additional hardware, making lung health monitoring more accessible and cost-effective for patients and healthcare providers.
Funding
$273.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing respiratory conditions like asthma and COPD often requires specialized equipment and time-consuming procedures, leading to delays in treatment and increased healthcare costs. Traditional methods may also lack the sensitivity needed for early detection and personalized monitoring of lung health.
Solution
Eupnoos offers a smartphone-based platform that analyzes breath sounds using acoustic biomarkers and AI to rapidly diagnose respiratory conditions. The app eliminates the need for additional hardware, making lung health monitoring more accessible and cost-effective. By analyzing unique breath sound patterns, the technology can identify disease markers associated with various lung pathologies, enabling healthcare providers to make informed decisions and tailor treatment plans. The platform supports differential diagnosis, ruling in or out conditions such as asthma, COPD, and restrictive diseases, and offers transparency in the diagnostic process.
Target Audience
The primary target audience includes healthcare providers, pulmonologists, and respiratory therapists seeking rapid, accurate, and cost-effective diagnostic tools for respiratory conditions, as well as patients who require accessible lung health monitoring.
Features
- Acoustic biomarker analysis using a smartphone app for respiratory condition diagnosis
- AI-powered algorithms for identifying disease markers in breath sounds
- Differential diagnosis capabilities for asthma, COPD, and restrictive diseases
- Monitoring of inhaled drug responses to ensure effective treatment
- Potential to uncover new biomarkers for assessing biologic therapy responses
- Support for established CPT reimbursement codes for healthcare providers
- Multi-model system for audio data acquisition and deep-learning method